Publications by authors named "Pedro E Cahn"

Claim this Profile
E
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
Sharon Walmsley, Don E Smith, Miguel Górgolas, Pedro E Cahn, Thomas Lutz

AIDS Res Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary: Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens.
Josep M Llibre, Pedro E Cahn, Tristan J Barber

Front Immunol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review.
Josep M Llibre, Pedro E Cahn, Janet Lo, Tristan J Barber, Cristina Mussini

Open Forum Infect Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Scott A Halperin, Lingyun Ye, Donna MacKinnon-Cameron, Bruce Smith, Pedro E Cahn

Lancet· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV.
Jeffrey V Lazarus, Kelly Safreed-Harmon, Adeeba Kamarulzaman, Jane Anderson, Ricardo Baptista Leite, Pedro E Cahn

Nat Commun· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver cirrhosis in HIV/HCV-coinfected individuals is related to NK cell dysfunction and exhaustion, but not to an impaired NK cell modulation by CD4 T-cells.
María L Polo, Yanina A Ghiglione, Jimena P Salido, Alejandra Urioste, Gabriela Poblete, Pedro E Cahn

J Int AIDS Soc· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.
Carina Cesar, Bryan E Shepherd, Alejandro J Krolewiecki, Valeria I Fink, Mauro Schechter, Pedro E Cahn

PLoS One· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[HBV and HCV co-infections in HIV positive patients in the "HAART era": new challenges].
Natalia L Laufer, Jorge F Quarleri, Maria B Bouzas, Hector M Perez, Horacio Salomon, Pedro E Cahn

Medicina (B Aires)· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.
Edgardo G Szyld, Eduardo M Warley, Laura Freimanis, René Gonin, Pedro E Cahn

AIDS· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
Pedro E Cahn, José M Gatell, Kathleen Squires, Lisa D Percival, Peter J Piliero

J Int Assoc Physicians AIDS Care (Chic)· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis